These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19226231)

  • 1. Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database.
    Srasuebkul P; Lim PL; Lee MP; Kumarasamy N; Zhou J; Sirisanthana T; Li PC; Kamarulzaman A; Oka S; Phanuphak P; Vonthanak S; Merati TP; Chen YM; Sungkanuparph S; Tau G; Zhang F; Lee CK; Ditangco R; Pujari S; Choi JY; Smith J; Law MG
    Clin Infect Dis; 2009 Apr; 48(7):940-50. PubMed ID: 19226231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD).
    Zhou J; Kumarasamy N;
    HIV Med; 2005 May; 6(3):216-23. PubMed ID: 15876289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
    Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer.
    De La Mata NL; Ly PS; Ng OT; Nguyen KV; Merati TP; Pham TT; Lee MP; Choi JY; Sohn AH; Law MG; Kumarasamy N
    Int J STD AIDS; 2017 Nov; 28(13):1282-1291. PubMed ID: 28632481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
    ; Young J; Psichogiou M; Meyer L; Ayayi S; Grabar S; Raffi F; Reiss P; Gazzard B; Sharland M; Gutierrez F; Obel N; Kirk O; Miro JM; Furrer H; Castagna A; De Wit S; Muñoz J; Kjaer J; Grarup J; Chêne G; Bucher H
    PLoS Med; 2012; 9(3):e1001194. PubMed ID: 22448150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database.
    Zhou J; Sirisanthana T; Kiertiburanakul S; Chen YM; Han N; Lim PL; Kumarasamy N; Choi JY; Merati TP; Yunihastuti E; Oka S; Kamarulzaman A; Phanuphak P; Lee CK; Li PC; Pujari S; Saphonn V; Law MG
    BMC Infect Dis; 2010 Dec; 10():361. PubMed ID: 21182796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.
    ; Lanoy E; May M; Mocroft A; Phillip A; Justice A; Chêne G; Furrer H; Sterling T; Monforte AD; Force L; Gill J; Harris R; Hogg RS; Rockstroh J; Saag M; Khaykin P; de Wolf F; Sterne JA; Costagliola D
    AIDS; 2009 Oct; 23(16):2199-208. PubMed ID: 19779320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
    Egger M; May M; Chêne G; Phillips AN; Ledergerber B; Dabis F; Costagliola D; D'Arminio Monforte A; de Wolf F; Reiss P; Lundgren JD; Justice AC; Staszewski S; Leport C; Hogg RS; Sabin CA; Gill MJ; Salzberger B; Sterne JA;
    Lancet; 2002 Jul; 360(9327):119-29. PubMed ID: 12126821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early mortality after late initiation of antiretroviral therapy in the TREAT Asia HIV Observational Database (TAHOD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Asia-Pacific.
    Rupasinghe D; Kiertiburanakul S; Kamarulzaman A; Zhang F; Kumarasamy N; Chaiwarith R; Merati TP; Do CD; Khusuwan S; Avihingsanon A; Lee MP; Ly PS; Yunihastuti E; Nguyen KV; Ditangco R; Chan YJ; Pujari S; Ng OT; Choi JY; Sim B; Tanuma J; Sangle S; Ross J; Law M
    HIV Med; 2020 Jul; 21(6):397-402. PubMed ID: 31852025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings.
    Kiertiburanakul S; Boettiger D; Ng OT; Van Kinh N; Merati TP; Avihingsanon A; Wong WW; Lee MP; Chaiwarith R; Kamarulzaman A; Kantipong P; Zhang F; Choi JY; Kumarasamy N; Ditangco R; Cuong DD; Oka S; Sim BLH; Ratanasuwan W; Ly PS; Yunihastuti E; Pujari S; Ross JL; Law M; Sungkanuparph S;
    AIDS Res Ther; 2017; 14():27. PubMed ID: 28484509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.